ClinicalTrials.gg
RecruitingNCT06774534Serpin-ARDSUpdated Mar 5, 2025

SerpinB3 Expression, PAR2 and SCCA-PD Polymorphism in Acute Respiratory Distress Syndrome

An observational study in Respiratory Distress Syndrome (RDS) and Respiratory Failure, sponsored by University of Padova. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-05.

Sponsored by University of Padova · Observational

How we know

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
40
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 91 studies in Respiratory Distress Syndrome with a site in Italy — 21 open to participants now, 24 under way, 2 of them phase 3. Respiratory Distress Syndrome · Italy.

Planned enrollment
30th of 39
40 · median 110
Started
2025
with 1 other
Observational
40 of 91
9 open now
Primary completion
2028-12
later than 22 of 23 live
Registered
88th of 91
by date
Lead sponsor
6 of 91
University of Padova

Among the 91 studies in Respiratory Distress Syndrome with a site in Italy, this one is the 30th largest by planned enrollment of the 39 observational ones that give a count, is one of 2 that started in 2025, is one of 40 observational ones, reaches primary completion later than 22 of the 23 other live ones, and was the 88th registered.

Respiratory Distress Syndrome

1,389 studies on the registry are indexed under Respiratory Distress Syndrome; 281 are open to participants now.

Browse Respiratory Distress Syndrome studies →

Open to participants now

21 of the 91 studies in Respiratory Distress Syndrome with a site in Italy are open now. Recruiting first, the newest first:

15 more — sign in →

All 21 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 196 Respiratory Distress Syndrome studies recruiting now, 116 (59%) set no upper age limit and 50 (26%) stop at 75 or younger; 52 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 91 studies in Respiratory Distress Syndrome with a site in Italy, or all of them as a file.
02

Study summary

The Acute Respiratory Distress Syndrome (ARDS) is a systemic syndrome characterized by severe respiratory failure, inflammation, loss of aerated tissue and high mortality. Recently, significant efforts have been made to phenotype ARDS patients through a wide range of new biomarkers and imaging indices with the goal of developing personalized treatments based on patient's biophenotypization. Recent literature demonstrates, both in vitro and in vivo but not yet in ARDS patients, that the serine protease inhibitor(SERPIN)-B3 plays a crucial role in the pathological mechanism of pulmonary fibrogenesis, and, similarly, protease-activated receptors(PAR2) is highly involved in this aberrant inflammatory response.

Consequently, studying the expression of SERPINB3 (including SCCA-PD polymorphism) and PAR2, in association with a detailed clinical and biomolecular phenotypization, could allow new insights into the pathophysiological mechanisms of lung injury during ARDS.

Read the detailed description

SERPINB3 is a strong activator of transforming growth factor-beta (TGF-b), an important pro-fibrogenic cytokine that also promotes epithelial-mesenchymal transition. Its expression can be induced/stimulated by oxidative stress. For example, in patients with idiopathic pulmonary fibrosis, the expression of SERPINB3 is significantly correlated with the presence of severe fibrosis and the expression of TGF-b. Recently, a new polymorphism of SERPINB3 (SCCA-PD) has been identified, featuring a single amino acid substitution in the reactive center loop of the protein, which enhances the functional anti-protease activity of this protein, inducing a more pronounced inflammatory and fibrotic response compared to wild-type SERPINB3, even in cultured monocytic cell lines. However, data is lacking in patients affected by ARDS. Furthermore, the reactive site loop of SERPINB3 has been shown to be essential for activating PAR2, another key element in the pro-fibrogenic cascade. PAR2 belongs to a subfamily of protease-activated G-protein-coupled receptors, consisting of four members, which plays a crucial role not only in activating the coagulation cascade and endothelendothelial inflammation but also in other stress-related clinical responses, such as pulmonary fibrosis. In conclusion, there is currently no data confirming a potential activation of the "SERPINB3-PAR2" pathway in ARDS patient, which is presumably involved in the pathway of severe lung injuries affecting ARDS patients.

More severe hyperinflammatory subphenotypes of ARDS are presumibely correlated with higher expression of SERPINB3, PAR2 and the presence of the SCCA-PD polymorphism. Thus, an early phenotypization of these critically ill patients could:

i) allow the identification and characterization of a subgroup of patients at higher risk of pulmonary fibrosis and death; and, ii) promote the development of new therapeutic strategies, that counteract the fibroproliferative process during ARDS avoiding the activation of "SERPINB3-PAR2" pathway, which could be a new pharmacological target for limiting the aberrant lung injury affecting ARDS patients (see 1-PPA).

Demographic, clinical, and ventilatory data will be collected in accordance with our institutional protocols until hospital discharge. All patients will undergo a high-resolution chest CT scan within 72 hours of ARDS diagnosis using a multidetector CT scan to assess the fibroproliferative changes typical of pulmonary fibrosis. A second high-resolution CT scan will be performed 21 ± 7 days after ARDS diagnosis or at hospital discharge, whichever occurs first, to monitor the evolution of fibroproliferative pulmonary changes.

Blood samples and BAL samples will be collected within 72 hours (and, only if available, at 21 ± 7 days) from ARDS diagnosis, as part of routine clinical practice. Only residual material will be used for research purposes.

03

Conditions studied

  • Respiratory Distress Syndrome (RDS)
  • Respiratory Failure

Keywords

  • ARDS
  • RESPIRATORY FAILURE
  • ICU
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Adult patients affected by ARDS and requiring IMV

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ARDS DIAGNOSIS
  • IMV

Exclusion criteria

Exclusion Criteria:

  • Age under 18 years
  • Pregnancy status
  • Lack of consent to participate in the study
  • to fiberoptic bronchoscopy and/or BAL (bronchoalveolar lavage)
  • Patients with chronic inflammatory skin conditions
  • Patients with chronic lung diseases
  • Patients with inflammatory respiratory diseases
  • Patients with neoplasms such as: squamous cell carcinoma of the cervix, squamous cell carcinoma of the esophagus, lung adenocarcinoma, breast adenocarcinoma, pancreatic adenocarcinoma, hepatocellular carcinoma
  • History of active or passive smoking
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
40 participants (estimated)
Patient registry
No

Groups and cohorts

  • CASES

    Patients affected by Acute Respiratory Distress Syndrome (ARDS) and needing invasive mechanical ventilation (IMV).

  • CONTROLS

    Patients admitted to the Intensive Care Unit and requiring IMV not for respiratory reasons.

06

What researchers measure

Primary outcomes

  1. SERPINB3

    Quantifying the expression of SERPINB3, PAR2 (measured in blood, bronchoalveolare lavage (BAL), and extracellular vesicles (EV)) in adult ARDS patients, requiring ventilatory support.

    Time frame: Within 72 hours from ARDS diagnosis

  2. SCCA-PD

    Quantifying the occurrence of SCCA-PD variant in adult ARDS patients, requiring ventilatory support.

    Time frame: Within 72 hours from ARDS diagnosis

Secondary outcomes

  1. FIBROSIS and SERPINB3, PAR2, SCCA-PD variant

    Investigating potential correlations between the Ichikado score (calculated on the CTscan performed after 21±7 days from ARDS diagnosis) and the expression of SERPINB3, PAR2 and the SCCA-PD variant.

    Time frame: At 21 days from ARDS diagnosis

  2. 60-DAY MORTALITY PREDICITVE MODELS

    Subsequently, identifying new models able to predict 60-day mortality according to anthropometric, clinical, respiratory parameters and laboratory data of lung damage (i.e., SERPINB3, PAR2, inflammatory cytokines (including TNF-a, TGF-ß ect) and cytofluorimetric measurements).

    Time frame: At 60-day after ARDS diagnosis

Other outcomes

  1. Only if available

    Quantifying the expression of SERPINB3, PAR2 (measured in blood, bronchoalveolare lavage (BAL), and extracellular vesicles (EV)) in adult ARDS patients, requiring ventilatory support.

    Time frame: At 21 days after ARDS diagnosis

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Dec 2028, 46 months after the start.

Of 228 non-industry observational studies under Respiratory Distress Syndrome, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 47. This study's planned 46 months is above that.

Counting every sponsor, half of 234 studies reached it within 24 months; a quarter within 12 and three quarters within 49.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 7, 2025
First posted
Jan 14, 2025
StartActual
Feb 28, 2025
Primary completionEst.
Dec 31, 2028
CompletionEst.
Dec 31, 2030
Last update
Mar 5, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06774534
Responsible party
Annalisa Boscolo (Professor, University of Padova) — Principal investigator
First posted
Jan 14, 2025
Start date
Feb 28, 2025
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2030 (estimated)
Last update
Mar 5, 2025

Study contacts

Annalisa Boscolo, Professor
Contact
annalisa.boscolo@gmail.com
+393498324972

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion